Table 2.
Incidence of ART-associated diarrhea [32]
| ART class | Reported incidence of diarrhea (%) |
|---|---|
| Protease inhibitors | |
| Lopinavir/ritonavir | 7–28 |
| Atazanavir/ritonavir | 2–3 |
| Darunavir/ritonavir | 9–14 |
| Nonnucleoside reverse transcriptase inhibitors | |
| Efavirenz | 3–14 |
| Nevirapine | <1–2 |
| Rilpivirine | <2 |
| Nucleoside reverse transcriptase inhibitors | |
| Tenofovir disoproxil fumarate | 9–16 |
| Abacavir | 7 |
| Integrase inhibitors | |
| Raltegravir | <1 |
| Dolutegravir | ~1 |
| Elvitegravira | 12 |
Adapted with permission from [32]
ART antiretroviral therapy
aCoformulated elvitegravir/cobicistat/emtricitabine/tenofovir